View 2 Images

A "breakthrough" Alzheimer's drug which has been rejected for use on the NHS can slow disease progression by eight years, researchers have revealed. The spending watchdog deemed the benefits of lecanemab "too small" to justify its cost , despite it being licensed for use in the UK.

But real-world data which compared people given the treatment from an early stage of the disease with those who had not been treated found that the drug could delay disease progression by more than eight years.

The findings, presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego, show that long-term treatment with lecanemab - also known as Leqembi - could delay progression from mild cognitive impairment to moderate Alzheimer's disease by 8.3 years among pati

See Full Page